Abstract Library

#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: SSA high dose,

#1642 Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus

Introduction: More than 10% of patient treated with Everolimus develop early onset of resistance. The lacking of adequate predictive factors in the targeted hera makes challenging the early identification of non-responders patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: cella c

Authors: Cella C, Spada F, Labanca V, Radice D, Rubino M,

Keywords: pancreatic nets, biomarker, everolimus,

#1497 Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs

Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kolasinska-Cwikla A

Authors: Kolasińska-Ćwikła A, Cwikła J, Bodei L, Sankowski A, Drozdov I,

Keywords: NETest, CgA, PCR,

#938 Clinical Characteristics of 144 patients (pts) Included in a Multidisciplinary Group, with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) G2 (WHO 2010). Grupo Argentum.

Introduction: Neuroendocrine tumors (NETs) G2 of the digestive tract are a heterogeneous group of tumors. Several treatment options including chemotherapy and target therapy are used, but there is a lack of prospective trials assessing the role of predictive factors in this population.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: OConnor J

Authors: O'Connor J, Pesce V, Bestanti C, Marmissolle F, Price P,

Keywords: neuroendocrine tumor, G2, survival,

#297 Hepatic Arterial Embolization v. Chemoembolization in Patients with Liver Metastases of Digestive Neuroendocrine Tumors

Introduction: Promising results have been reported using hepatic arterial chemoembolization (CE) or embolization (E) alone in patients with liver metastases of DET, but these modalities have not been compared.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: MAIRE F, Catherine L, Dermot O, Marie-Pierre V, Philippe R,

Keywords: liver metastases, carcinoid tumors, embolization, chemoembolization, prospective trial,